GHENT, Belgium, 6 March 2017 – Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that its partner, Merck KGaA , has presented new data from a Phase Ib study demonstrating strong efficacy with the bi-specific anti-IL-17A/F Nanobody® in patients with moderate-to-severe chronic plaque psoriasis. The results were presented at the 75th Annual Meeting of the American Academy of Dermatology Conference, taking place from 3-7 March 2017, in Orlando, Florida.
Category: Orlando, FL
Celgene to Present New Data from Clinical Trials on Oral OTEZLA…
Celgene Corporation today announced that findings from ongoing clinical trials of OTEZLA , the Company’s oral, selective inhibitor of phosphodiesterase 4 , conducted in patients with moderate or moderate to severe plaque psoriasis, and in adult patients with active psoriatic arthritis, will be presented at the 75th Annual Meeting of the American Academy of Dermatology in Orlando, Florida. Ten abstracts will be presented at the meeting.
Sequence Health to Show Healthcare Providers How to Improve Outcomes…
Sequence Health will host an educational seminar on improving outcomes and increasing the number of surgeries performed by optimizing the patient journey through the healthcare continuum at the 2017 Healthcare Information and Management Systems Society conference, attended by 40,000 health IT professionals, clinicians, and healthcare executives. Entitled Increase Surgical Procedures and Patient Outcomes, the information packed session is scheduled for February 22, 12:30pm – 12:50pm inside Booth 7281 at the Orange County Convention Center in Orlando, Florida.
Class 1 Malocclusions: To Treat or Not to Treat?
There’s good news and bad news when it comes to Class 1 malocclusions in horses. The good news is that these are the mildest misalignments, and some don’t even require treatment.